Personalized ESA doses for anemia management in hemodialysis patients with end-stage renal disease

James Rogers, Edward J. Gallaher, David Dingli

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


End-stage renal disease (ESRD) patients receiving hemodialysis are typically anemic due to a lack of erythropoietin (EPO), a hormone required for red blood cell (RBC) production. EPO replacement therapy is complex, often resulting in oscillating hemoglobin (Hb) levels. EPO dosing protocols do not account for endogenous delays and appear to contribute to, if not cause, Hb variability. The Mayo Clinic Anemia Management System (MCAMS) is based on a physiological simulation of the production and lifespan of RBCs, driven by EPO dosage schedules. Patient-specific parameters were found such that simulated Hb levels matched historical Hb levels in response to historical EPO doses. The calibrated model was used to identify new dosing regimens that stabilize Hb. MCAMS has been used to recommend individualized EPO dosage regimens to maintain stable Hb levels within a desired target range for more than 600 patients, improving patient outcomes while reducing medication costs by about 40 percent.

Original languageEnglish (US)
Pages (from-to)121-153
Number of pages33
JournalSystem Dynamics Review
Issue number1-2
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Social Sciences (miscellaneous)
  • Strategy and Management
  • Management of Technology and Innovation


Dive into the research topics of 'Personalized ESA doses for anemia management in hemodialysis patients with end-stage renal disease'. Together they form a unique fingerprint.

Cite this